Is the routine use of bevacizumab in the treatment of women with advanced or recurrent cancer of the cervix sustainable?

Background: New chemotherapy combinations are being tested for the treatment of women with advanced, persistent or recurrent cervical cancer. We sought to evaluate the cost effectiveness of some newer combination therapies in cervical cancer.

Patients And Methods: A cost effectiveness decision model was used to analyze Gynecologic Oncology Group 240.